Look back at pharma news in the week to February 7, 2020
By Barbara Obstoj-Cardwell. Editor
Last week’s news included Bristol-Myers Squibb deciding to pull its application with the European Medicines Agency for the combination of its top-selling drug Opdivo with Yervoy for certain cancer patients. US biotech Biogen had a boost last Wednesday when it prevailed in a patent dispute with Mylan over multiple sclerosis drug Tecfidera. On the research front and in the face of the ever-increasing impact of the coronavirus epidemic, Gilead Sciences joined the fight with its investigational antiviral remdesivir and entering trials in China, and GlaxoSmithKline linked up with the Coalition for Epidemic Preparedness Innovations. Last week also saw the US Food and Drug Administration and the Federal Trade Commission announce a cooperation on making biosimilars more accessible. And, along with its 2019 financial results, US pharma giant Merck & Co said it plans to spin out its established products into a new company.
Bristol-Myers filing withdrawal set up another US vs EU conflict
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze